The Golden Age of Income

Jack talks with Barclays analyst Seth Sigman and Barron’s reporter Sabrina Escobar about the once-great growth stock. Learn more about your ad choices. Visit megaphone.fm/adchoices

Jack answers listener questions with help from Barron's colleague Elizabeth O'Brien.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Vanguard's Joseph Davis talks about megatrends, including the tug of war between AI and US government deficits. UBS's Mark Haefele discusses investing where governments spend.   Learn more about your ad choices. Visit megaphone.fm/adchoices

After a muted IPO, the A.I. stock is soaring. Coreweave co-founder Brannin McBee breaks down the business. Barron's senior writer Adam Levine shares some points to consider.  Learn more about your ad choices. Visit megaphone.fm/adchoices

After decades of making sense only on paper, ex-US markets are suddenly shining.  Nanette Abuhoff Jacobson from Hartford Funds says it’s just the start.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Bonds took a hit this week. BlackRock's Russ Brownback explains why that's an opportunity, and what investors should do now.   Learn more about your ad choices. Visit megaphone.fm/adchoices

Jack looks at how the humble credit score has made investors more than 100,000%. Plus, Barron's reporter Mackenzie Tatananni answers a question about Wolfspeed. Learn more about your ad choices. Visit megaphone.fm/adchoices

The market has bounced back from its 'Liberation Day' lows, but tariff shake-ups aren't over. What does that mean for you? Jack sits down with Bhanu Baweja, Chief Strategist at UBS Investment Bank. Learn more about your ad choices. Visit megaphone.fm/adchoices

Jack gives his thoughts on the market rebound, and previews Disney earnings. Plus, Allspring Portfolio Manager Bryant VanCronkhite gives us some stock picks, and explains why he's going with value over growth. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this vacation non-episode, Jack talks about Lilly’s latest trial breakthrough and the mysteries of federal budget reconciliation.  Learn more about your ad choices. Visit megaphone.fm/adchoices